Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
16.94
-0.61 (-3.48%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cartesian Therapeutics Employees
As of December 31, 2023, Cartesian Therapeutics had 38 total employees, including 37 full-time and 1 part-time employees.
Employees
38
Change
n/a
Growth
n/a
Revenue / Employee
$1,261,526
Profits / Employee
-$7,431,026
Market Cap
430.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Community Health Systems | 61,000 |
| Perspective Therapeutics | 119 |
| Y-mAbs Therapeutics | 100 |
| PureTech Health | 90 |
| Olema Pharmaceuticals | 74 |
| Terns Pharmaceuticals | 66 |
| Altimmune | 59 |
| Mind Medicine (MindMed) | 57 |
RNAC News
- 1 hour ago - Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - GlobeNewsWire
- 10 days ago - Cartesian Therapeutics: Uncertainty Remains - Seeking Alpha
- 13 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 5 weeks ago - Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results - Seeking Alpha
- 2 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - GlobeNewsWire
- 5 months ago - Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik - GlobeNewsWire